These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 28699928)

  • 1. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY VERSUS PHOTODYNAMIC THERAPY IN THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO CENTRAL SEROUS CHORIORETINOPATHY.
    Peiretti E; Caminiti G; Serra R; Querques L; Pertile R; Querques G
    Retina; 2018 Aug; 38(8):1526-1532. PubMed ID: 28699928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ANTIANGIOGENICS IN CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH LASER IN CENTRAL SEROUS CHORIORETINOPATHY.
    Chhablani J; Pichi F; Silva R; Casella AM; Murthy H; Banker A; Nowilaty SR; Carrai P; Nucci P; Arevalo JF;
    Retina; 2016 May; 36(5):901-8. PubMed ID: 27115855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy.
    Smretschnig E; Hagen S; Glittenberg C; Ristl R; Krebs I; Binder S; Ansari-Shahrezaei S
    Eye (Lond); 2016 Jun; 30(6):805-11. PubMed ID: 26965012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal anti-vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization.
    Kang HM; Koh HJ
    Am J Ophthalmol; 2013 Apr; 155(4):713-9, 719.e1. PubMed ID: 23219069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between anti-vascular endothelial growth factor therapy and photodynamic therapy for myopic choroidal neovascularization.
    Matsuo M; Honda S; Matsumiya W; Kusuhara S; Tsukahara Y; Negi A
    Eur J Ophthalmol; 2012; 22(2):210-5. PubMed ID: 21534251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
    Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H
    Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up.
    Arevalo JF; Espinoza JV
    Graefes Arch Clin Exp Ophthalmol; 2011 Aug; 249(8):1159-66. PubMed ID: 21448811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy.
    Wong IY; Shi X; Gangwani R; Zhao P; Iu LP; Li Q; Ng A; Li X
    BMC Ophthalmol; 2015 Jun; 15():66. PubMed ID: 26122636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization.
    Yoon JU; Byun YJ; Koh HJ
    Retina; 2010 Mar; 30(3):418-24. PubMed ID: 20094012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
    Lazic R; Gabric N
    Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing efficacy of reduced-fluence and standard-fluence photodynamic therapy in the treatment of polypoidal choroidal vasculopathy.
    Ngo WK; Chee WK; Tan CS; Lim TH
    BMC Ophthalmol; 2020 Apr; 20(1):150. PubMed ID: 32293353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
    Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
    Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation in Visual Outcome to Anti-Vascular Endothelial Growth Factors in Choroidal Neovascular Membrane Developing in Eyes with Previously Untreated Versus Focal Laser-Treated Central Serous Chorioretinopathy.
    Roy R; Saurabh K; Das D; Panigrahi PK; Das S; Pal SS; Jain A
    Semin Ophthalmol; 2017; 32(6):781-786. PubMed ID: 27533737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early response to the treatment of choroidal neovascularization complicating central serous chorioretinopathy: a OCT-angiography study.
    Sacconi R; Tomasso L; Corbelli E; Carnevali A; Querques L; Casati S; Bandello F; Querques G
    Eye (Lond); 2019 Nov; 33(11):1809-1817. PubMed ID: 31267094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of neovascular central serous chorioretinopathy to an extended upload of anti-VEGF agents.
    Schworm B; Luft N; Keidel LF; Hagenau F; Kern C; Herold T; Kortuem KU; Priglinger SG; Siedlecki J
    Graefes Arch Clin Exp Ophthalmol; 2020 May; 258(5):1013-1021. PubMed ID: 32112141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY: The Fujisan Study.
    Gomi F; Oshima Y; Mori R; Kano M; Saito M; Yamashita A; Iwata E; Maruko R;
    Retina; 2015 Aug; 35(8):1569-76. PubMed ID: 25830698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy.
    Bae SH; Heo JW; Kim C; Kim TW; Lee JY; Song SJ; Park TK; Moon SW; Chung H
    Am J Ophthalmol; 2011 Nov; 152(5):784-92.e2. PubMed ID: 21742303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia.
    Parodi MB; Iacono P; Papayannis A; Sheth S; Bandello F
    Arch Ophthalmol; 2010 Apr; 128(4):437-42. PubMed ID: 20142520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of treatment response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for choroidal neovascularisation secondary to chronic central serous chorioretinopathy.
    Romdhane K; Zola M; Matet A; Daruich A; Elalouf M; Behar-Cohen F; Mantel I
    Br J Ophthalmol; 2020 Jul; 104(7):910-916. PubMed ID: 31615761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.
    Moon SW; Kim MS; Kim ES; Yu SY; Kwak HW
    Ophthalmologica; 2011; 225(3):169-75. PubMed ID: 21273795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.